What Is Alcohol Withdrawal Syndrome?
Alcohol Withdrawal Syndrome (AWS) is a set of symptoms that occur when a person with chronic, heavy alcohol use abruptly reduces or stops consumption. Unlike withdrawal from other substances, alcohol withdrawal can be potentially fatal if not treated appropriately — representing a medical emergency at its most severe grades.
Alcohol is the most widely consumed psychoactive substance worldwide, and alcohol use disorder is one of the most prevalent psychiatric conditions. AWS occurs because the brain adapts to the chronic presence of alcohol and, when it is withdrawn, enters a state of hyperexcitability that can progress to seizures and delirium tremens.
Recognizing alcohol dependence as a medical illness — and withdrawal as a condition that requires supervised treatment — can save lives. Safe detoxification is the first step toward recovery, but it should not be carried out without professional guidance in cases of severe dependence.
Potentially Fatal
Severe alcohol withdrawal (delirium tremens) carries 5-15% mortality without treatment. It is one of the few withdrawal syndromes that can kill.
Brain Hyperexcitability
Chronic alcohol suppresses the nervous system. Withdrawal triggers a glutamatergic hyperexcitability rebound that explains tremors, seizures, and delirium.
Treatment Saves Lives
Supervised detoxification with benzodiazepines reduces delirium tremens mortality to less than 1%. Adequate treatment is essential.
Pathophysiology
Understanding alcohol withdrawal rests on the imbalance between inhibitory (GABA) and excitatory (glutamate) neurotransmission. Alcohol chronically potentiates GABA action and inhibits glutamate. The brain compensates by increasing glutamate receptors and reducing GABAergic sensitivity.
GABA-Glutamate Imbalance
When alcohol is suddenly removed, the nervous system enters a state of hyperexcitability: GABAergic (inhibitory) activity is reduced and glutamatergic (excitatory) activity is increased. This excitotoxicity causes tremors, anxiety, tachycardia, and, in severe cases, seizures and delirium.
Autonomic Hyperactivity
Excessive activation of the sympathetic nervous system causes tachycardia, hypertension, sweating, tremors, and fever. In its extreme form, this autonomic hyperactivity can be fatal due to cardiac arrhythmias, malignant hyperthermia, or cardiovascular collapse.
Symptoms
AWS symptoms follow a predictable temporal progression. They begin 6-12 hours after the last dose, progress in severity over the first 24-72 hours, and, without treatment, can progress to seizures and delirium tremens. Severity depends on the amount and duration of use, age, and prior withdrawal episodes.
Manifestations of Alcohol Withdrawal Syndrome
- 01
Tremors (6-12h)
Earliest withdrawal symptom. Tremor in hands, tongue, and eyelids. Worsens with activity and emotional stress. The most sensitive clinical sign.
- 02
Anxiety and agitation
Restlessness, irritability, insomnia. Related to sympathetic hyperactivity and reduced GABAergic activity.
- 03
Nausea and vomiting
Frequent during the first 24-48 hours. Can cause dehydration and electrolyte disturbances if not managed.
- 04
Sweating and tachycardia
Autonomic hyperactivity manifestations. Heart rate >100 bpm and profuse sweating signal severity.
- 05
Arterial hypertension
Blood pressure rises from sympathetic activation. Can be significant and requires monitoring.
- 06
Hallucinations (12-24h)
Visual, tactile, or auditory hallucinations with preserved consciousness ("alcoholic hallucinosis"). Different from delirium tremens, the patient recognizes that the hallucinations are not real.
- 07
Seizures (24-48h)
Generalized tonic-clonic seizures. Occur in 5-15% of cases. Can be the first manifestation in some patients. Risk of status epilepticus.
- 08
Delirium tremens (48-96h)
Severe mental confusion, disorientation, intense agitation, vivid hallucinations, fever, severe tachycardia. Medical emergency with 5-15% mortality without treatment.
Diagnosis
The diagnosis of AWS is clinical. The CIWA-Ar scale (Clinical Institute Withdrawal Assessment for Alcohol - Revised) is the gold standard for quantifying withdrawal severity and guiding pharmacological treatment. The AUDIT scale (Alcohol Use Disorders Identification Test) identifies problematic alcohol use.
🏥DSM-5 Criteria for Alcohol Withdrawal
Fonte: American Psychiatric Association — DSM-5
Criterion A: stopping or cutting back heavy, prolonged alcohol use
- 1.Stopping or significantly cutting back alcohol use after a prolonged period of heavy use
Criterion B: 2 or more symptoms hours to days after cessation
At least 2 symptoms must be present- 1.Autonomic hyperactivity (sweating, tachycardia >100 bpm)
- 2.Increased hand tremor
- 3.Insomnia
- 4.Nausea or vomiting
- 5.Transient visual, tactile, or auditory hallucinations
- 6.Psychomotor agitation
- 7.Anxiety
- 8.Generalized tonic-clonic seizures
Specifiers
- 1.With perceptual disturbances (hallucinations with intact reality testing)
- 2.Exclude medical conditions that mimic withdrawal (infection, head trauma, hepatic encephalopathy)
CIWA-AR SCALE — WITHDRAWAL SEVERITY
| SCORE | SEVERITY | MANAGEMENT |
|---|---|---|
| <10 | Mild | Outpatient treatment possible. Monitoring and support. Oral thiamine. |
| 10-18 | Moderate | Pharmacotherapy with benzodiazepines. Regular monitoring. Consider hospitalization. |
| 19-25 | Severe | Hospital admission recommended. Intravenous benzodiazepines. Continuous monitoring. |
| >25 | Very severe / Delirium tremens | ICU. High-dose benzodiazepines. Cardiorespiratory support. Risk of death. |
DIFFERENTIAL DIAGNOSIS
Differential Diagnosis
Delirium Tremens vs Delirium of Other Cause
- Fever, confusion, hallucinations in an alcoholic
- Investigate infection/head trauma as alternative cause
- Delirium in an alcoholic = urgent hospital admission
Diagnostic Tests
- Head CT
- Complete blood count
- Cultures
Wernicke Encephalopathy
- Triad: ophthalmoplegia, ataxia, confusion
- B1 deficiency
- Wernicke = urgent IV thiamine before any glucose
Diagnostic Tests
- Clinical
- Response to thiamine
- MRI
Hypoglycemia
- Tremor, sweating, confusion
- Alcoholics have depleted glycogen reserves
- Low glycemia
- Hypoglycemia = immediate treatment
Diagnostic Tests
- Capillary glycemia
Seizure of Other Etiology
- Seizure without alcohol withdrawal
- Structural lesion
- Pro-convulsant medication
Diagnostic Tests
- EEG
- Head CT/MRI
Acute Pancreatitis
- Intense epigastric pain radiating to the back
- Nausea and vomiting
- Elevated lipase
Diagnostic Tests
- Amylase/lipase
- Abdominal ultrasound
Neurological Emergencies: Wernicke and Delirium
Wernicke Encephalopathy is a neurological emergency caused by acute thiamine (vitamin B1) deficiency, common in malnourished alcoholics. The clinical triad — ophthalmoplegia (paralysis of eye movements), ataxia (impaired gait coordination), and mental confusion — may be incomplete. The golden rule: in an alcoholic with any neurological sign, give intravenous thiamine BEFORE any glucose — glucose without thiamine can precipitate Wernicke in depleted patients.
Delirium tremens (DTs) and delirium from other causes must be distinguished, since management differs. In an alcoholic who develops agitation, confusion, hallucinations, and fever, beyond alcohol withdrawal, alternative causes must be investigated: infection (pneumonia, UTI, meningitis), head trauma (subdural hematoma is more common in alcoholics), hypoglycemia, and hepatic insufficiency. Head CT, complete blood count, and cultures are indicated in any delirium.
Seizures in Withdrawal
Alcohol-related seizures typically occur 6-48 hours after the last dose, are generally generalized tonic-clonic, and can appear without other prominent withdrawal signs. The critical diagnostic question is whether the seizure is caused by alcohol withdrawal or another etiology — structural lesion (hematoma, tumor), CNS infection, metabolic disturbance, or primary epilepsy.
Indicators for additional investigation (CT/MRI, EEG): first lifetime seizure; focal seizure (not generalized); prolonged postictal state; focal neurological déficit; high fever; recent trauma; no documented withdrawal. A documented alcohol withdrawal seizure in a patient with a typical prior history within an adequate temporal window can be managed clinically without emergency neuroimaging, but each case requires careful evaluation.
Metabolic and Hepatic Complications
Chronic alcoholics have multiple metabolic vulnerabilities that surface during withdrawal. Hypoglycemia is particularly important: alcohol inhibits hepatic gluconeogenesis, and glycogen reserves are often depleted. Capillary glycemia should be checked immediately in any patient with altered consciousness. Hyponatremia, hypokalemia, hypomagnesemia, and hypophosphatemia are common and require replacement.
Acute pancreatitis can occur alongside withdrawal — alcohol is a major cause of pancreatitis. Intense epigastric pain radiating to the back, nausea, and vomiting in an alcoholic should raise suspicion. Elevated lipase confirms it. Severe acute pancreatitis is a life-threatening medical emergency. Alcoholic liver disease can also present with jaundice and hepatic encephalopathy during withdrawal, which require different management from delirium tremens.
Treatment
AWS treatment involves two phases: acute management of withdrawal (safe detoxification) and long-term relapse prevention. Benzodiazepines are the cornerstone of acute treatment, acting as GABAergic substitutes that prevent seizures and delirium tremens.
PHARMACOTHERAPY IN ALCOHOL WITHDRAWAL
| PHASE | MEDICATION | MECHANISM | CONSIDERATIONS |
|---|---|---|---|
| Acute | Diazepam / Lorazepam | GABAergic agonist — prevents seizures and delirium | Diazepam for fixed protocol; lorazepam if hepatic insufficiency |
| Acute | Thiamine (B1) IV/IM | Prevention of Wernicke encephalopathy | ALWAYS before IV glucose. 500mg IV for 3 days, then oral |
| Acute | Electrolyte correction | Magnesium, potassium, phosphate replacement | Hypomagnesemia lowers seizure threshold |
| Maintenance | Naltrexone | Opioid antagonist — reduces craving and the pleasure of drinking | First line for relapse prevention. Oral or monthly injectable. |
| Maintenance | Acamprosate | Glutamatergic modulation — reduces withdrawal discomfort | Safe in hepatic insufficiency. Effective for maintaining sobriety. |
| Maintenance | Disulfiram | Inhibits acetaldehyde dehydrogenase — aversive reaction to alcohol | Requires patient motivation. Psychological "umbrella" effect. |
Hours 0-24
CIWA-Ar assessment. Start benzodiazepines based on severity. IV thiamine before any glucose solution. Correct electrolyte disturbances.
Days 2-5
Continuous CIWA-Ar monitoring. Taper benzodiazepines gradually. Watch for seizures and delirium tremens (peak at 48-72h). Hydration and nutrition.
Weeks 1-2
Acute symptoms resolve. Start maintenance pharmacotherapy (naltrexone or acamprosate). Psychiatric evaluation for comorbidities.
Months 1-6
Psychotherapy (CBT, motivational interviewing). Support groups (AA, SMART Recovery). Treat comorbidities (depression, anxiety, PTSD).
6-12+ months
Maintain sobriety. Prevent relapse. Regular follow-up. Functional and social rebuilding.
Acupuncture as Treatment
Acupuncture, especially the NADA auricular protocol (National Acupuncture Detoxification Association), is used as complementary therapy in alcohol dependence treatment programs around the world. The protocol uses five specific auricular points and is applied in a group setting, facilitating access.
Proposed mechanisms include endogenous opioid system modulation (endorphin and enkephalin release), HPA axis regulation with reduced cortisol, increased GABAergic activity, and dopaminergic modulation in reward circuits. These mechanisms may help reduce craving, anxiety, and insomnia associated with withdrawal.
Acupuncture is used as an adjunct to conventional treatment and does not replace pharmacotherapy or psychotherapy. It is especially used in the maintenance phase, to manage anxiety, insomnia, and residual craving. Hundreds of dependence treatment programs in the US and Europe include the NADA protocol in their services.
Prognosis
With adequate acute-phase treatment, withdrawal mortality drops from 5-15% to less than 1%. The long-term prognosis of alcohol dependence depends on engagement in continued treatment: with multidisciplinary follow-up, about 50-60% of patients maintain sobriety in the first year.
Factors associated with a good prognosis include: solid social support, employment, no severe psychiatric comorbidities, engagement in support groups, and maintenance pharmacological treatment. Relapse risk is highest in the first 90 days and drops progressively.
Relapse is common and should not be seen as failure. It is estimated that 40-60% of patients relapse in the first year. However, each period of sobriety brings health benefits and each treatment attempt increases the chances of lasting recovery.
Myths and Facts
Myth vs. Fact
Alcoholism is a lack of character or a moral choice.
Alcohol use disorder is a brain disease with genetic (40-60% heritability), neurobiological, and environmental roots. It involves measurable changes in reward circuits, impulse control, and stress regulation. Treating it as a moral failing keeps people from seeking treatment and perpetuates suffering.
Myth vs. Fact
A person can stop drinking abruptly without risk.
Alcohol withdrawal can be fatal. Seizures and delirium tremens are potentially lethal complications. People with heavy and prolonged alcohol use should NEVER stop abruptly without medical supervision. Safe detoxification with benzodiazepines saves lives.
Myth vs. Fact
If the person doesn't hit 'rock bottom', treatment is useless.
The earlier the treatment, the better the prognosis. Waiting for 'rock bottom' means allowing dependence to cause more organic, social, and psychological damage. Early interventions, even when the patient is still ambivalent, are effective and recommended.
When to Seek Help
If you or someone you know shows signs of alcohol dependence or is experiencing withdrawal symptoms, seek medical help. Safely stopping alcohol in cases of dependence requires professional supervision.
Frequently Asked Questions about Alcohol Withdrawal
Alcohol acts as a central nervous system depressant by potentiating GABA (inhibitory) and inhibiting glutamate (excitatory). With chronic use, the brain compensates: it reduces GABA receptors and increases NMDA glutamate receptors. When stopping abruptly, the system becomes hyperexcited — without the alcohol "brake" and with an increased glutamatergic "accelerator". This causes: autonomic hyperexcitability (tremor, tachycardia, sweating, hypertension), seizures, and, in severe cases, delirium tremens. Unlike opioid withdrawal (very uncomfortable but rarely fatal), severe alcohol withdrawal can kill.
The temporal progression is characteristic: 6-12 hours — fine hand tremor, anxiety, sweating, nausea, tachycardia (mild to moderate symptoms); 12-24 hours — more intense symptoms, possible hypertension, hallucinations (generally visual) without confusion — "alcoholic hallucinosis"; 24-48 hours — peak risk of tonic-clonic seizures; 48-72 hours — risk of delirium tremens: severe confusion, hallucinations, fever, extreme agitation, autonomic instability. The CIWA-Ar scale objectively assesses severity.
Delirium tremens (DTs) is the most severe complication of alcohol withdrawal, with 5-15% mortality without treatment. It occurs in 3-5% of withdrawal patients. Signs: intense mental confusion (disorientation to time, place, and person), vivid hallucinations (usually visual — animals, insects), extreme agitation, fever, tachycardia, hypertension, profuse diaphoresis, and severe tremor. Typically appears 48-96 hours after the last dose. It is a medical emergency requiring immediate hospital admission.
It depends on dependence severity. Mild to moderate drinkers can attempt outpatient cessation under medical supervision. Heavy drinkers and chronic dependents — especially those with a history of prior seizures or delirium tremens, daily drinking for many weeks, or withdrawal symptoms on waking — should NOT stop abruptly without medical supervision. The physician will assess severity with specific scales and determine whether hospital or supervised outpatient benzodiazepine detoxification is needed.
Wernicke Encephalopathy is caused by acute thiamine (B1) deficiency — common in alcoholics, since alcohol impairs thiamine absorption and use. The clinical triad: ophthalmoplegia (difficulty moving the eyes), ataxia (gait instability), and mental confusion. Fundamental rule: give 200-500 mg intravenous thiamine BEFORE any glucose in an alcoholic with neurological changes — glucose before thiamine can precipitate or worsen Wernicke in a depleted patient. Untreated, it can progress to Korsakoff Syndrome (permanent amnesia).
Evidence on auricular acupuncture (NADA protocol, 5 points) in alcohol dependence is limited and heterogeneous — systematic reviews (Cochrane) found no robust evidence of superiority over placebo/sham on primary outcomes, although some trials suggest specific benefits for anxiety, insomnia, and craving. Proposed mechanisms (dopaminergic/endogenous opioid, parasympathetic modulation) are hypothetical and only partially investigated. Some rehabilitation programs use it as an adjunct, never as sole treatment — pharmacotherapy (benzodiazepines in the acute phase; naltrexone/acamprosate in maintenance) and psychotherapy remain the cornerstones.
In the acute phase: benzodiazepines (diazepam, lorazepam, oxazepam) — the gold standard, substituting for alcohol at GABA receptors and preventing seizures/DTs; IV thiamine (Wernicke prophylaxis); and electrolyte correction. For relapse prevention: naltrexone (reduces pleasure and craving for alcohol); acamprosate (reduces residual glutamatergic hyperstimulation and craving); and disulfiram (causes an unpleasant reaction if drinking — deterrent effect). The physician will choose the regimen based on severity and the patient's context.
Chronic alcohol use causes multiple brain changes: cerebellar and prefrontal córtex atrophy (cognitive, executive deficits); hippocampal damage (memory impairment, possibly progressing to Korsakoff Syndrome); alcoholic peripheral neuropathy (pain and tingling in limbs); alcoholic cardiomyopathy; and progressive liver damage (alcoholic hepatitis, cirrhosis). With prolonged abstinence, the brain can partially recover (neuroplasticity) — especially in younger patients and those with shorter use histories.
DSM-5 unified the concepts under "Alcohol Use Disorder" (AUD), graded as mild (2-3 criteria), moderate (4-5 criteria), and severe (6+ criteria). Criteria include: drinking more than intended, trying to stop and being unable to, much time spent drinking, intense craving, failing in obligations because of alcohol, continuing to drink despite problems, abandonment of activities, risky situations (drunk driving), tolerance (needing to drink more for the same effect), and withdrawal. Severe AUD (dependence) involves profound neurobiological alterations that require specialized treatment.
Hospital admission is indicated when: there is a history of seizures or DTs in prior withdrawals; moderate to severe symptoms on assessment (CIWA-Ar >15); heavy daily use for a prolonged period (>8 units/day for weeks); outpatient treatment has failed; adequate social support for monitoring is lacking; severe medical comorbidities (hepatic insufficiency, pneumonia, trauma); or pregnancy. Hospitalization allows continuous monitoring and benzodiazepine adjustment as symptoms evolve.
Related Reading
Deepen your knowledge with related articles